Divine Aleru, Microbiome Signatures Research Coordinator

This meta-analysis confirms that regional resistance patterns heavily influence H. pylori eradication success. In areas with low metronidazole and high clarithromycin resistance, AM significantly outperforms AC. These findings support microbiome-informed, resistance-guided therapy selection.

This large study confirms that prior metronidazole exposure significantly reduces H. pylori eradication rates with QT. Extending treatment to 14 days restores effectiveness. The findings highlight the microbiome-relevant impact of antibiotic history and support individualized treatment planning.

This review established metronidazole as the standard treatment for giardiasis, highlighting its microbial mechanism, resistance patterns, and microbiome-disruptive potential. The authors call for individualized, microbiome-aware therapy that balances efficacy with host-microbial homeostasis.

This clinical trial found that metronidazole significantly reduced inflammation—especially SR and L-6 levels—in OVID-19 pneumonia. The results support its immunomodulatory effects beyond infection control and encourage its careful use as a microbiome-sensitive anti-inflammatory agent.

This study demonstrated that metronidazole reduces inflammation and pro-inflammatory cytokines in a murine model, suggesting its anti-inflammatory properties are independent of antimicrobial action. These findings highlight its potential in microbiome-modulating therapies for non-infectious inflammation.

This study shows metronidazole significantly reduces inflammation and blood loss in SAID enteropathy. It likely acts by targeting anaerobic microbes that drive neutrophil-mediated damage, offering a microbiome-relevant intervention for small intestinal injury.

This review dissected the metabolism, cytotoxic intermediates, and resistance mechanisms of metronidazole. It confirmed its microbial dependence for activation, its broad microbiome-disruptive potential, and the emerging resistance pathways beyond nim genes—emphasizing a shift toward targeted, microbiome-sparing alternatives in clinical practice.

This review confirms metronidazole’s high efficacy in treating I protozoal infections while raising microbiome and resistance concerns. Its targeted use remains standard in acute infections, but clinicians should monitor duration and microbial consequences to reduce long-term harm and support stewardship.

This review explores metronidazole’s clinical efficacy, safety concerns, and microbiome impact. It confirms its value in treating anaerobic infections but highlights potential neurotoxic and genotoxic risks. The review calls for more human studies and microbiome-focused evaluations to guide safer, more targeted antimicrobial use.

This randomized trial showed oral metronidazole matched V administration in preventing infections after open appendectomy for nonperforated appendicitis, suggesting a cost-effective and microbiome-conscious alternative.